Literature DB >> 19390939

Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer.

Marc Buyse1.   

Abstract

Meta-analysis is the statistical process of combining information from several studies addressing the same question. Meta-analyses based on individual patient data are far more reliable and informative than those based on summary statistics obtained from the trialists or extracted from the published literature. Meta-analysis of randomized clinical trials may contribute to therapeutic progress through (1) establishing efficacy benefits beyond a reasonable doubt, (2) identifying sources of heterogeneity between trials, (3) studying subsets reliably, (4) confirming differences in toxicity profiles, (5) evaluating the cost-effectiveness of experimental therapies, (6) assessing surrogate endpoints, and (7) addressing ancillary questions. All of these potential contributions are illustrated with examples in early and advanced colorectal cancer.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19390939     DOI： 10.1007/s10147-009-0879-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


  42 in total

1.  Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. Meta-Analysis Group In Cancer.

Authors:  I Durand-Zaleski; B Roche; M Buyse; R Carlson; M O'Connell; P Rougier; A E Chang; V K Sondak; M Kemeny; T Allen-Mersh; P L Fagniez; J P Le Bourgeois; P Piedbois
Journal:  Crit Rev Oncol Hematol       Date:  1999-11       Impact factor: 6.312

2.  Meta-analyses of published results are unreliable.

Authors:  M Buyse; R W Carlson; P Piedbois
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

3.  Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer.

Authors:  P Thirion; N Wolmark; E Haddad; M Buyse; P Piedbois
Journal:  Ann Oncol       Date:  1999-11       Impact factor: 32.976

Review 4.  Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments.

Authors:  Pascal Piedbois; Marc Buyse
Journal:  Curr Opin Oncol       Date:  2008-07       Impact factor: 3.645

5.  On the relationship between response to treatment and survival time.

Authors:  M Buyse; P Piedbois
Journal:  Stat Med       Date:  1996-12-30       Impact factor: 2.373

6.  Issues of efficiency in combining proportions of deaths from several clinical trials.

Authors:  M Buyse; L M Ryan
Journal:  Stat Med       Date:  1987 Jul-Aug       Impact factor: 2.373

7.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group.

Authors:  L A Stewart; M J Clarke
Journal:  Stat Med       Date:  1995-10-15       Impact factor: 2.373

8.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

Authors:  P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

Review 9.  Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer.

Authors:  Laurent Zelek; Pascal Piedbois; Marc Buyse
Journal:  Expert Rev Anticancer Ther       Date:  2002-08       Impact factor: 4.512

10.  Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.

Authors:  Junichi Sakamoto; Yasuo Ohashi; Chikuma Hamada; Marc Buyse; Tomasz Burzykowski; Pascal Piedbois
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544
View more
  5 in total

1.  The ARCAD clinical trials program: an update and invitation.

Authors:  Daniel J Sargent; Marc Buyse; Alastair Matheson; Richard M Goldberg; Aimery de Gramont
Journal:  Oncologist       Date:  2012-02-02

Review 2.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

3.  Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.

Authors:  Stefan Michiels; Everardo D Saad; Marc Buyse
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

4.  Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Authors:  Beth Sherrill; James A Kaye; Rickard Sandin; Joseph C Cappelleri; Connie Chen
Journal:  Onco Targets Ther       Date:  2012-10-23       Impact factor: 4.147

5.  Meta-analysis of randomized clinical trials in the era of individual patient data sharing.

Authors:  Takuya Kawahara; Musashi Fukuda; Koji Oba; Junichi Sakamoto; Marc Buyse
Journal:  Int J Clin Oncol       Date:  2018-01-12       Impact factor: 3.402
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.